Cost of Venous Thromboembolic Disease in Patients with Lung Cancer: Costecat Study.

Ana Rosa Rubio-SalvadorVicente Escudero-VilaplanaJosé Antonio Marcos RodríguezIrene Mangues-BafalluyBeatriz Bernárdez Carlos García ColladoRoberto Collado-BorrellMaría Dolores Alvarado FernándezJosé Ignacio Chacón López-MuñizMaría Yébenes CortésManuel Gómez BarreraMiguel Ángel Calleja-Hernández

Published in: International journal of environmental research and public health (2021)

Venous thromboembolism episodes induce an economic impact on patients and healthcare systems. Direct healthcare costs are the major burden of the total cost, in which hospitalizations are the main drivers of cost.

Keyphrases

healthcare
venous thromboembolism
end stage renal disease
ejection fraction
newly diagnosed
patient reported outcomes
patient reported